Capricor Therapeutics Announces Plans to Pursue a

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Capricor Therapeutics Announces Plans to Pursue a Cenderitide Clinical Program and Enters Into Research Support Agreement With Insulet Corporation

LOS ANGELES, Oct. 9, 2014 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (OTCBB: CAPR ), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases, today announced that it plans to develop a clinical program using Cenderitide for the treatment of post-acute heart failure using Insulet's drug delivery system based on the OmniPod ® insulin management system.

Additionally, Capricor announced that it has entered into an Investigator-Initiated Research Support Agreement (the "Agreement") with Insulet Corporation (Nasdaq: PODD ). Pursuant to the Agreement, Insulet will support Capricor's research by engaging in certain product development, project management and design control activities in addition to product supply for the planned clinical trial. 

Dr. Linda Marbán, Chief Executive Officer of Capricor, said, "Recent positive results in Novartis' PARADIGM-HF trial have shown the mechanism of action of their ARNI (angiotensin receptor neprilysin inhibitor) can raise the level of endogenous natriuretic peptides by preventing their enzymatic breakdown in chronic heart failure patients. We believe this validates the mechanism of action of Cenderitide, which is a dual receptor natriuretic peptide agonist. We intend to develop Cenderitide as an outpatient therapy to be delivered continuously for up to 90 days after discharge from the hospital to patients who have been admitted for acute decompensated heart failure (ADHF). There are currently no treatments on the market that specifically target the stabilization and reduction of the early re-hospitalization rate of acute decompensated heart failure patients."

According to the American Heart Association, heart failure is the leading cause of hospitalization among adults older than 65 years of age in the United States and is responsible for over 1 million hospital admissions annually. Among those patients that have been admitted, approximately 24% are re-hospitalized in one month, and 50% are re-hospitalized in six months.

Dr. Linda Marbán, continued, "These staggering statistics, coupled with the prevalence and incidence of heart failure increasing around the world, leads us to believe this could be an extremely exciting market opportunity for Capricor. We are pleased to announce our pursuit of this key clinical program with Insulet's support as we continue to execute on our strategy to bring Cenderitide back into the clinic. We are planning a clinical trial to commence in early 2015. Of note, we have been granted Fast-Track designation by the FDA for the post-acute development program for Cenderitide."

Currently, there are no drugs on the market targeting the post-acute period, 90 days following a hospital admission for Acute Decompensated Heart Failure (ADHF). Cenderitide's treatment goal and target indication is prevention of re-hospitalization in heart failure patients during the post-acute hospitalization period.

About Cenderitide

Cenderitide belongs to a class of drugs called natriuretic peptides. Preclinical and clinical data have shown that the natriuretic peptide class can act on multiple disease processes that play a role in negative outcomes associated with heart failure. Cenderitide is designed as an outpatient therapy to be delivered continuously using a validated subcutaneous infusion pump for up to 90 days (the "post-acute" period) following a hospital admission for ADHF. Cenderitide was designed by scientists at the Mayo Clinic to be the only dual natriuretic peptide receptor agonist.

Cenderitide is currently not an approved product and is strictly for investigational purposes.

About Capricor Therapeutics

Capricor Therapeutics, Inc. (CAPR), a publicly traded biotechnology company, is focused on the development of novel therapeutics to prevent and treat heart disease. The Company has two leading product candidates: CAP-1002 and Cenderitide. The Company was formed through the November 2013 merger between Capricor, Inc., a privately held company whose mission is to improve the treatment of heart disease by commercializing cardiac stem cell therapies for patients, and Nile Therapeutics, Inc., a clinical-stage biopharmaceutical company developing innovative products for the treatment of cardiovascular diseases. For additional information visit www.capricor.com .

About Insulet Corporation

Insulet Corporation (Nasdaq: PODD ) is an innovative medical device company primarily focused on making it easier for people living with diabetes to manage their disease. Through its OmniPod Insulin Management System, Insulet seeks to expand the use of insulin pump therapy among people with insulin-dependent diabetes. The OmniPod is a revolutionary and easy-to-use tubeless pump that features just two parts and fully-automated cannula insertion. The OmniPod technology has also been adapted to deliver additional drugs in other disease states. Insulet has also developed variations of the OmniPod to allow for delivery of drugs to treat other medical conditions. Founded in 2000, Insulet Corporation is based in Billerica, Mass. For more information, please visit:  http://www.myomnipod.com .

Cautionary Note Regarding Forward-Looking Statements

Statements in this press release regarding the efficacy, safety, and intended utilization of Capricor's product candidates; the conduct, size, timing and results of discovery efforts and clinical trials; plans regarding regulatory filings, future research and clinical trials; plans regarding current and future collaborative activities and the ownership of commercial rights; future royalty streams, and any other statements about Capricor's management team's future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "believes," "plans," "could," "anticipates," "expects," "estimates," "should," "target," "will," "would" and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements. More information about these and other risks that may impact our business are set forth in our Form 10-K for the year ended December 31, 2013, as filed with the Securities and Exchange Commission on March 31, 2014, in our Amendment No. 1 to Registration Statement on Form S-1, as filed with the Securities and Exchange Commission on May 23, 2014, and in our Form 10-Q for the quarter ended June 30, 2014, as filed with the Securities and Exchange Commission on August 14, 2014. All forward-looking statements in this press release are based on information available to us as of the date hereof, and we assume no obligation to update these forward-looking statements.

Capricor Therapeutics, Inc. AJ Bergmann, Vice President of Finance +1-310-358-3200 ProActive Capital Group Kirin Smith, COO +1-646-863-6519 www.ProActiveCapital.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Elisity’s Texas Water Pilot Puts IonQ’s Deal in View

Updated Category News Views 45

Water-system security is not a place for chest-thumping Elisity’s role in Texas Project Watershed 250 lands on a problem that is painfully concrete: water and wastewater utilities have to keep pumps, treatment systems and plant operations running while trying to close cybersecurity gaps. That is a tougher job than selling another dashboard to a corporate IT department....

Continue Reading
Ross Pools Joins Forces with Florida Panthers in 2026

Updated Category News Views 327

An Unlikely Team-Up: Pools and Hockey Well, here's one for the books: a South Florida pool company hitching its wagon to an NHL team. Ross Pools, the folks who’ve been carving out backyard oases in the sizzling Florida sun for over two decades, are now officially aligned with the Florida Panthers. Yeah, the same Panthers that snatched the Stanley Cup not once but twice...

Continue Reading
Arbor Realty Trust Faces Securities Fraud Allegations

Updated Category News Views 108

Securities Lawsuit Against Arbor Realty Trust Looms Well, here we go again. Another day, another securities lawsuit hitting the headlines. This time it's Arbor Realty Trust (NYSE: ABR) getting caught in the crossfire, accused of pulling the wool over investors' eyes. Seems like 'truth in advertising' is just part of the PR playbook for some big shots. Understanding the...

Continue Reading
Sabre Unveils AI Travel Tech: A Bold New Frontier

Updated Category News Views 110

Sabre's Game-Changing AI Travel Integration I'm no stranger to bold moves in the travel industry, but what Sabre's rolling out tomorrow might just be the biggest leap we've seen in a while. They're unleashing what's called the first global travel plug-in within Grok Bot, marking a significant shake-up in the travel tech sphere. Too many tech upgrades in this business...

Continue Reading
Snowhawk Enters Telarus as Digital Demand Gets Serious

Updated Category News Views 17

Telarus just pulled another serious capital partner into the room, and that matters more than the usual law-firm victory lap. Snowhawk Partners has invested in the technology services distributor alongside Columbia Capital, which remains a long-standing partner. Nobody disclosed a valuation, ownership percentage, financing mix, or closing date. Annoying? Sure. But the...

Continue Reading
Graphic Packaging Shakes Up Leadership and Supply Chain

Updated Category News Views 226

New Leadership Takes the Helm at Graphic Packaging What do you do when you want to streamline an operation that spans continents? Well, if you're Graphic Packaging Holding Company (NYSE: GPK), you bring in fresh leadership to serenade the chaos into a well-oiled machine. Starting December 1, 2026, D. Keith Hamilton will be sinking his teeth into North America Mills &...

Continue Reading
Palm Beach Loan Company Tests Luxury Lending Demand

Updated Category News Views 0

Jewelry in a safe is dead capital until somebody lends against it. That plain fact sits behind Luxury Asset Capital's latest move: the launch of Palm Beach Loan Company, a South Florida brand aimed at wealthy owners of watches, diamonds, art, handbags, gold, collectibles, and other high-value possessions. The company is not asking clients to sell the stuff they spent...

Continue Reading
Tenax Class Action: Investors Alley Fight for Redress

Updated Category News Views 179

Tenax Therapeutics in Hot Water Over Drug Trial Results Amidst the ever-unpredictable tides of the pharmaceutical industry, here comes a doozy – Tenax Therapeutics, Inc. is neck-deep in a shareholder lawsuit. If you tossed some money at NASDAQ:TENX anytime between November 13, 2023, and August 7, 2026, you might be feeling the sting of regret, and rightly so. What Went...

Continue Reading
Greenberg Traurig Cheers Clients' 69th GRAMMY® Nods

Updated Category News Views 124

A Momentous Occasion for Greenberg Traurig's Entertainment Clients Oh, the glamour and glitz of the music world! There's nothing quite like the GRAMMY® Awards to stir up a blend of excitement, ego, and anxiety in the industry. This time around, the lawyers over at Greenberg Traurig are beaming with pride as their clients scoop up nominations for the 69th Annual GRAMMY®...

Continue Reading
Portillo's Faces Legal Heat: Investor Class Action Filed

Updated Category News Views 268

What’s Eating Portillo's? Ah, once upon a misstep in the land of promising expansion, now we have Portillo's Inc. (NASDAQ: PTLO) neck-deep in legal hot water. Those golden fries and famous sandwiches somehow didn't pave the way for stockholder bliss. Why the turmoil? On an ordinary November morning, the DJS Law Group made it clear: They're rallying the troops for a...

Continue Reading

Top 5 Most Recently Viewed Articles

Exciting New Dining and Shopping Experiences Coming to Cotino

Updated Category News Views 309

Exciting Developments at Cotino Bay Beach A vibrant new community is set to emerge with the opening of Cotino Bay Beach, Dining and Shops in fall 2026. The first Storyliving by Disney community is gearing up to offer an array of dining and retail experiences, creating a unique destination for residents and visitors alike. Restaurants to Enrich the Community Among the...

Continue Reading
dsm-firmenich Expands Share Repurchase Program for Growth

Updated Category News Views 227

Introduction to the Share Repurchase Program dsm-firmenich, a leader in nutrition, health, and beauty, has embarked on a significant share repurchase program with the aim of enhancing shareholder value and strategically managing its capital. By initiating this buyback, dsm-firmenich demonstrates its commitment to returning value to its investors while still investing in...

Continue Reading
Investigation into Arvinas, Inc. Over Securities Fraud Claims

Updated Category News Views 561

Investigation of Arvinas, Inc. Pomerantz LLP is looking into potential claims on behalf of investors of Arvinas, Inc. (NASDAQ: ARVN). This investigation aims to uncover whether the company and its executives may have engaged in securities fraud or other illegal business practices. Recent Developments Arvinas has recently communicated significant changes to its clinical...

Continue Reading
Gantry Enhances Mortgage Banking with Triad Capital Acquisition

Updated Category News Views 145

Gantry got its hands on Triad Capital Advisors back in 2023, and it was no small move. This merger wasn't just about beefing up their operational muscle; it expanded Gantry's footprint in the Midwest finance scene big time. It’s like they dropped a bomb on their competitors without warning—traders watching closely could feel the shift coming. With this acquisition,...

Continue Reading
Port Athena Debuts with PENETRON Solution in Tartu

Updated Category News Views 32

The Emergence of Port Athena in Tartu Move over, sleepy towns—Tartu's staking its claim with the Port Athena development. What we're looking at is more than just another block of buildings. It's practically a new district, nestled on the banks of the Emajõgi River. Forget the stereotypical old-world charm; we're talking sleek, modern architecture that's ready to become...

Continue Reading